Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.
The study will evaluate treatments with:
ASP2215 Plus Azacitidine
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.
Leukemia and Lymphomas MCL
Mantle cell lymphoma (MCL) Oncternal Study
Now enrolling patients for a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies.
This research study will evaluate an investigational drug, called cirmtuzumab, in combination with a standard drug, called ibrutinib (Imbruvica®), for treatment of patients with MCL.
Myelofibrosis Abbvie Study
Now Enrolling Patients for a Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis.